Deciphera Pharmaceuticals, Inc. (DCPH) Financials
Stock symbol DCPH is outdated, potentially delisted? Maybe it is available on other exchange?
DCPH Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2024 | 420.9 million | 104.9 million |
| Dec. 31, 2023 | 473.6 million | 122.7 million |
| Sept. 30, 2023 | 497.8 million | 116.2 million |
| June 30, 2023 | 509.6 million | 105.2 million |
DCPH Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2024 | -54.7 million | 10.2 million |
| Dec. 31, 2023 | -28.9 million | 14.1 million |
| Sept. 30, 2023 | -29.9 million | 11.2 million |
| June 30, 2023 | -38.9 million | 12.9 million |
DCPH Net Income
No data available :(
DCPH Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2024 | 272.5 million | 21.4 million | 21.4 million |
| Dec. 31, 2023 | 306.2 million | 22.4 million | 25.9 million |
| Sept. 30, 2023 | 339.1 million | 23.3 million | 26.7 million |
| June 30, 2023 | 328.7 million | 24.2 million | 27.5 million |
DCPH Shares Outstanding
DCPH Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2024 | 146000 | 57.4 million | 32.8 million | - |
| Dec. 31, 2023 | 63000 | 58.6 million | 39.1 million | - |
| Sept. 30, 2023 | 62000 | 62.5 million | 33.3 million | - |
| June 30, 2023 | 293000 | 58.3 million | 32.6 million | - |
DCPH Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2024 | 45.0 million | 3.7 million |
| Dec. 31, 2023 | 48.3 million | 1.8 million |
| Sept. 30, 2023 | 43.3 million | 1.3 million |
| June 30, 2023 | 38.3 million | 173000 |
DCPH Revenue by Segment
Graph available only for paid members. Upgrade to see it.
DCPH
Price: $25.59
52 week price:
Earnings Per Share: -2.21 USD
P/E Ratio: -6.67
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 800800
Ebitda: -12.0 millionMarket Capitalization: 2.2 billion